Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch AI could spot dangerous thyroid Flare-Ups

NCT ID NCT07017907

Diagnosis Sponsor: THYROSCOPE INC. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a software called Glandy HYPER that uses artificial intelligence to detect thyrotoxicosis—a dangerous overactive thyroid state—in people with Graves' disease. The AI analyzes resting heart rate data from wearable devices like smartwatches and compares it with standard blood tests. Researchers will enroll 15 adults with Graves' disease to see how well the software performs, but its results will not be shared with participants or affect their medical care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Heart rate-based AI software for detecting thyrotoxicosis
What this could lead to
If successful, this AI tool could offer a non-invasive way to monitor thyroid storms using wearable devices, potentially improving early detection.
What could go wrong
This is a small, early-stage study with only 15 participants, so results may not apply broadly. The software is not FDA-approved and is for research only.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 22 years and older with a confirmed diagnosis of Graves' disease, including both newly diagnosed and currently treated individuals. Participants will be recruited from a single center in the United States. All participants must be able to use a wearable device and provide informed consent.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 22 years or older, regardless of sex. * Individuals who are newly diagnosed with Graves' disease or currently undergoing treatment for it. * Individuals who have received sufficient explanation about the investigational software and are able to use it appropriately. * Individuals who voluntarily agree to participate in the study and have signed informed consent, either directly or via a legally authorized representative. Exclusion Criteria: * Individuals with cardiac conditions such as arrhythmia or heart failure. * Individuals taking medications that significantly affect heart rate, including antiarrhythmics or antihistamines. (Intermittent short-acting beta-blockers are allowed.) * Pregnant or breastfeeding individuals, or those planning pregnancy during the study period or not using appropriate contraception. * Individuals with significant comorbidities that interfere with follow-up or study compliance. * Individuals with severe psychiatric disorders, substance use disorder, or alcohol dependence. * Individuals deemed ineligible at the discretion of the investigator for safety or ethical concerns.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Graves disease hyperthyroidism thyrotoxicosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves disease Hyperthyroidism/thyrotoxicosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Umesh Masharani

    RECRUITING

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.